Guangzhou Innocare Pharma Tech Co Ltd

1. Quantitatively analyze the total radioactivity in excreta after a single oral administration of [14C]ICP-332 to healthy subjects, obtain data on human radioactive excretion rate, and study the main excretion pathways. 2. Quantitatively analyze the total radioactivity in whole blood (if applicable) and plasma after a single oral administration of [14C]ICP-332 to healthy subjects. Obtain the pharmacokinetic (PK) parameters of total radioactivity in plasma and whole blood (if applicable), and investigate the distribution of total radioactivity in whole blood and plasma (if applicable). 3. Obtain the metabolite profiles in plasma, urine, and feces after a single oral administration of [14C]ICP-332 to healthy subjects, identify the main metabolites, and determine the metabolic pathways and elimination pathways of ICP-332 in the human body.

To evaluate the efficacy of ICP-332 in subjects with moderate to severe atopic dermatitis

1. Evaluate the safety and tolerability of ICP-332 in the treatment of adult subjects with moderate to severe atopic dermatitis (AD). 2. Evaluate the efficacy of ICP-332 in the treatment of moderate to severe AD using the Eczema Area and Severity Index (EASI) score. 3. Other efficacy endpoints and patient-reported outcomes of ICP-332 in the treatment of adult subjects with moderate to severe AD. 4. Evaluate the pharmacokinetic (PK) characteristics of ICP-332 in adult subjects with moderate to severe AD.